Hims & Hers Health Inc - HIMS STOCK NEWS

Hims & Hers Health has announced the acquisition of Sigmund NJ (Trybe Labs), an at-home lab testing facility, to introduce comprehensive lab testing capabilities through its platform. The acquisition, funded through cash on hand, will enable the company to support at-home blood draws and whole body testing using blood lancets.

The new service will allow customers to test hormone levels, cardiac risk, stress markers, cholesterol, liver function, thyroid function, and prostate health. This expansion will facilitate the company's entry into new clinical categories including low testosterone, perimenopausal and menopausal support. The de-identified lab data will also enhance the company's AI developments, including MedMatch.

The integration of lab testing aims to provide more precise clinical decision-making and personalized treatment plans. Hims & Hers plans to roll out at-home testing to customers over the next year.

Hims & Hers Health (NYSE: HIMS) has launched two new customer-focused initiatives: the Health Collective and the Community Member Council. The Health Collective is an ambassador program open to active customers, allowing them to connect with other members, share experiences, and get early access to new products. The Community Member Council consists of 15 hand-selected members who will directly influence the platform's future development by providing feedback on products, services, and experiences.

These programs align with the company's mission to enhance global health and wellness while building stronger relationships with customers. According to Chief Commercial Officer Mike Chi, the initiatives will help improve customer experience and care by actively incorporating user feedback into the platform's development.

Hims & Hers Health (NYSE: HIMS), the leading health and wellness platform, has announced it will release its fourth quarter and full year 2024 financial results after market close on Monday, February 24, 2025. The company will host a conference call to discuss the results at 5:00 p.m. ET on the same day.

Investors can access the conference call by dialing (888) 510-2630 (U.S.) or (646) 960-0137 (international) with conference ID 1704296. A live audio webcast will be available on the company's investor relations website and archived for one year.

Additionally, the company's management team will participate in the Morgan Stanley Technology, Media & Telecom Conference on March 4, 2025 in San Francisco.

Hims & Hers (NYSE: HIMS) has released 'The Shape of America' report, providing insights into Americans' relationship with weight in 2024. Based on a survey of 5,000 adults, key findings reveal that 83% of Americans are not at their desired weight, with respondents wanting to lose an average of 42 pounds. The study shows that 75% of Americans think about their weight daily, with 14% considering it constantly.

Notable findings include: 85% believe weight loss would improve major life aspects, 81% think they'd save money on household expenses if they lost weight, and 47% attempt weight loss yearly, seasonally, or constantly. The report also highlights that individuals with obesity are 50% more likely to skip work due to their weight and 2.5X more likely to withdraw from activities and social plans.

Hims & Hers Health (NYSE: HIMS) has been named to Inc.'s 2024 Best in Business list in the Health Products category. The recognition celebrates companies that have achieved significant milestones and made substantial impacts on their industries and society.

The company, which focuses on providing access to high-quality, affordable personalized care, has demonstrated remarkable business growth and customer impact across its platform. Their core specialties include sexual health, dermatology, mental health, and weight loss. Hims & Hers leverages innovative solutions in technology, operations, and customer experience to improve healthcare accessibility and standards.

Inc.'s Best in Business list acknowledges companies from various sectors, including technology, healthcare, finance, and retail, that have achieved exceptional execution in areas such as customer expansion, product launches, and increased market share.

Hims & Hers Health (NYSE: HIMS) has expanded its weight loss offerings by introducing daily meal replacement bars and shakes, available through subscription starting at $110 per month. The new nutrition products, developed by registered dietitians, include protein-packed bars with 15g of protein and shakes containing 27-30g of protein, along with essential vitamins and minerals. The comprehensive weight management program includes personalized treatment plans, medication management, nutritional guidance, weekly meal plans, and 24/7 access to care teams through their platform.

Hims & Hers Health (NYSE: HIMS) announced two key leadership appointments to strengthen its quality and safety standards. Deb Autor, former FDA deputy commissioner, joins the board of directors, bringing over 30 years of pharmaceutical and regulatory experience. Janet Stevens, a pharmaceutical quality expert previously with Hillrom and Pfizer, joins as Global Head of Quality & Safety. Both appointments reinforce the company's commitment to clinical excellence and safety across its health and wellness platform.

Hims & Hers Health (NYSE: HIMS) has revealed significant challenges in accessing branded GLP-1 medications across the US, with nearly 80,000 individuals on their platform reporting access difficulties. The company has launched a GLP-1 Supply Tracker to gather data on medication accessibility issues. In just one week, almost 7,000 individuals reported inability to access medications, particularly those containing semaglutide. In Texas, which ranks among the top 10 states for obesity rates, nearly 5,000 Hims & Hers customers reported access problems. Research shows that about 30% of Weight Loss customers previously prescribed branded GLP-1s couldn't fill their prescriptions due to unavailability.

Hims & Hers Health (NYSE: HIMS) reported strong Q3 2024 results with revenue reaching $401.6 million, up 77% year-over-year. The company achieved net income of $75.6 million and Adjusted EBITDA of $51.1 million. Subscriber base grew 44% to 2.0 million users. Monthly online revenue per average subscriber increased 24% to $67, while AOV rose 48% to $147. The company raised its full-year 2024 guidance, expecting revenue between $1.460-1.465 billion and Adjusted EBITDA of $173-178 million. Gross margin was 79%, and the company generated $85.3 million in operating cash flow.